Trial · NCT03355768
Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
NCT03355768, Phase 3, Withdrawn, Jennifer Amengual
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL. Trials, record NCT03355768. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03355768
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
- NCT number
- NCT03355768
- Status
- Withdrawn
- Phases
- Phase 3
- Enrollment
- 0 participants, actual
- Lead sponsor
- Jennifer Amengual
- Conditions
- Lymphoma, T-Cell, Peripheral
- Interventions
- Romidepsin, Pralatrexate
- First posted
- 2017-11-28
- Last updated
- 2018-12-19
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival | up to 3 years | Compare the progression free survival (PFS) in patients with R/R PTCL treated with romidepsin versus the combination of romidepsin plus pralatrexate. |
| Secondary | Complete Response (CR) | up to 3 years | Contrast the complete response rate (CR) for patients treated with romidepsin or romidepsin plus pralatrexate. |
| Secondary | Duration of response (DOR) | up to 3 years | Contrast the duration of response (DOR) for patients treated with romidepsin or romidepsin plus pralatrexate. |
| Secondary | Overall survival (OS) | up to 3 years | Contrast the overall survival (OS)for patients treated with romidepsin or romidepsin plus pralatrexate. |
| Secondary | Overall response rate (ORR) | up to 3 years | Contrast the overall response rate (ORR) for patients treated with romidepsin or romidepsin plus pralatrexate. |
| Secondary | Time to Treatment Progression (TTP) | up to 3 years | TTP measured for patients with relapsed or refractory PTCL treated with romidepsin or romidepsin plus pralatrexate. |
| Secondary | Time to Relapse (TTR) | up to 3 years | TTR measured for patients with relapsed or refractory PTCL treated with romidepsin or romidepsin plus pralatrexate. |
| Secondary | Maximum Number of Treatment Cycles | Up to 6 months | Describe the maximum number of cycles and planned dose intensity of all drugs in both arms in patients with R/R PTCL treated with romidepsin or romidepsin plus pralatrexate. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03355768
GET https://conductscience.org/api/trials/v1/NCT03355768/registered